ACTION_REQUIRED: no
REVIEWED_SNAPSHOT: 1253735cafb47e0bae661e6d6385c18387e653ea68a99d5d3b18f2614011aefb

# Independent post-run review — COMP-044

- Reviewer: `/root/comp044_post_review_v30` (context-isolated)
- Manifest: five design files, two generated outputs, and 54 proposed updates; every byte count and SHA-256 matched.
- Gate continuity: all five design hashes match the approved pre-run snapshot `3ac3044399d576331db0c55167e6a5c421f9024d437f61889ef6978704303967`; only the two authorized outputs changed during execution.
- Method: static, read-only inspection; the reviewer did not edit or rerun the experiment.

## Verdict

Clean with limitations. The implementation, outputs, narrow interpretation, and complete corrective propagation are internally consistent. The resolved queue item may be deleted.

## Supported conclusion

COMP-019's unconditional flat-dose classification is not robust to COMP-044's tested substrate-occupancy and finite-window diagnostics.

COMP-044 supplies no replacement physiological regime, effective dose, ΔSUA or serum effect, genotype ordering, efficacy model, topology or chassis winner, production-sufficiency conclusion, additivity conclusion, peroxide-safety clearance, or clinical-efficacy conclusion.

## Closure findings

- The equations, units, 1,620-cell-per-dose factorial, named scenarios, regime counts, and verdict reproduce the implementation.
- Grid occupancy is sensitivity-space occupancy, not probability; only the ratio-one boundary has direct mass-balance meaning.
- ALLN-346 Studies 201 and 202 are separated; SSS11 is not presented as the first *C. utilis*-derived UOX clinical program.
- CRISPR UOX evidence remains limited to edited human hepatocyte cultures and spheroids in vitro.
- COMP-001 remains a P1/P1′ plus pLDDT proxy with empirical validation §1.10 required.
- H08 remains Open with survival count 0; H01 remains Pending with survival count 0.
- Q00511 is the *A. flavus* UOX record; P78609 is the *C. utilis* / *Cyberlindnera jadinii* UOX record.
- GWAS and clinical-phenotype rows corrected during remediation are labeled Human Observational, not Clinical Trial.
- Exact configurations precede §1.33, and separate §1.36 safety testing precedes animal escalation.
- Reader-facing propagation contains no personal treatment instructions, engineered-UOX home use, parent-status transfer, or unsupported topology, chassis, additivity, dose, or production claim.

## Review limits

The inherited 8.3 U/mg activity, Km range, 2–4-hour window, and 233 mg/day denominator were not requalified as physiological planning inputs. Dynamic luminal replenishment, transport, oxygen kinetics, peroxide safety, retained activity, and serum-urate response remain unmodeled empirical questions.
